The first laureates of the project "Foresight of health":

"Foresight of Health": the course for innovation
A.P. Danilova, Wiki-Meds

On November 22, the first award ceremony for the winners of the international project to support innovative pharmacy and medicine "Foresight of Health" was held at the Crocus-Expo exhibition center with the support of the Public Organization "Business Russia" and the State Duma. 
Foresight of Health is designed to promote the development of innovative technologies and developments in the field of pharmacy and biotechnology to improve the quality and increase human life expectancy in Russia and the world. The project "Foresight of Health" celebrates medicines, scientific developments, persons who have made a tangible contribution to the development of innovative pharmacy and medicine.

For the first time in the history of the pharmaceutical and medical industry, the best innovative developments were identified and publicly presented. The project brought together more than 250 representatives working in different segments of medicine and pharmacy: medical institutes, research institutes, pharmaceutical companies, innovation centers, etc.

In six nominations, the largest representatives of the pharmaceutical industry, scientists, higher educational institutions were represented, which, according to the expert council of the project, became the best in the field of innovative medicine and pharmacy.

• In the nomination "Innovative Pharmacy", in the sub–nomination "Medicinal product", the winner was the drug "Amixin", the manufacturer is the company "Pharmstandard".
• Pfizer became the winner in the nomination "Innovative Pharmacy", in the sub-nomination "Manufacturer".
• In the nomination "Innovative Biotechnology", in the sub-nomination "Medicinal product", the first was the drug "Aranesp" of the company "Amgen".
• In the same nomination, in the "Manufacturer" sub-nomination, the winner was Amgen.
• In the nomination "Scientific contribution", in the sub-nomination "Scientific Group", the winner was a scientific group led by Valery Ivanovich Chissov, Institute named after Peter Alexandrovich Herzen.
• In the same nomination, in the sub-nomination "Scientist", the winners were Vladislav Isaakovich Deigin, Anatoly Vladimirovich Pokrovsky and Olga Mikhailovna Ipatova.
• In the next nomination – "Research Innovation", in the sub-nomination "Research School", the Lomonosov Moscow State University, Faculty of Fundamental Medicine was awarded.
• In the nomination "Research innovation", in the sub-nomination "R&D company", the winner was the company "Himrar".
• In the nomination "Recognition of the industry", in the sub-nomination "Person", the winner was Dmitry Morozov.
• In the "Company" sub-nomination, the winner was the company "Biocad". In the same nomination, in the sub-nomination "Industry Professional Association", the winner was the "Association of Russian Pharmaceutical Manufacturers".
• In the nomination "Recognition of patients", in the sub-nomination "Innovative project", the winner was the company "Himrar Ventures".
• In the sub-nomination "Innovative company", the winner was the company "Pharmstandard".
• In the nomination "Recognition of patients", in the sub-nomination "Innovative drug", the winner was the drug "Glivek".

Also, the organizing committee of the project noted the drugs and companies of the industry with special sub-nominations.

• In the nomination "Research innovation", in the special sub-nomination "Discovery in the diagnosis of tuberculosis", the winner was the drug "Diaskintest", the company "Pharmstandard".
• In the nomination "Innovative biotechnology", in the special sub–nomination "For contribution to the fight against diabetes mellitus", the winner was the drug "Biosulin", the producer is the company "Pharmstandard".

Kudlay Dmitry Anatolyevich, MD, Deputy General Director for Marketing and Promotion of biotechnological drugs of JSC "Pharmstandard": "It is an honor that Russian research teams and developments are noted in this project. We saw that the words "modernization" and "innovation" have a real component. I would like to note that in today's economic realities, our company is distinguished by a systematic approach in the development and implementation of modern recombinant drugs that meet all health requirements."

• "For a breakthrough in the treatment of anemia" in the nomination "Innovative biotechnology", the drug "Eralfon" was awarded, the manufacturer is the company "Sotex".

Egorov Andrey Vilionarovich, Executive Director of Sotex: "We are glad that our drug, which really makes life easier for people with anemia, has attracted attention. Currently, Sotex is implementing a strategy to expand its product portfolio, actively participates in the national import substitution program, and also continues to develop innovations in the field of biotechnology. We will continue to strive to create new, highly effective drugs."

The partners of the project were pharmaceutical companies whose products embodied the latest promising, innovative ideas and technologies in the world of pharmacy.

The strategic partner was Novo Nordisk, a world leader and innovator in the treatment of diabetes mellitus.

Sergey V. Smirnov, Vice President of Novo Nordisk: "The innovative path of development in the pharmaceutical business is a special path that can be compared to the voyage of Odyssey between Scylla and Charybdis. On the one hand, there is a danger of bringing an insufficiently tested drug to the market, on the other hand, procrastination can negate all the expected success. To stay on the only right course is the highest art, great courage and endless responsibility. I want the key word here to always remain the word responsibility. The Novo Nordisk company fully supports the initiatives of the project organizers, and in the future we plan fruitful cooperation."

The company "Chiesi" has become an official partner of the international project "Foresight of Health", and, according to the general director of the company, Yuri Fedorovich Litvishchenko, in conditions when the whole country is in search of innovative products, it is very important to unite the forces of all those who are interested in it. Yuri Litvishchenko believes that this project will give impetus to the implementation of innovative developments. And it is the partnership of Russian and foreign companies, which this project contributes to, that will help in the implementation of innovative projects in Russia.

The project partner is Amgen. Amgen is a leader in the biotechnology industry because it was one of the first to reveal the potential of a new generation of effective and safe medicines to provide patients with innovative methods of treating the most serious diseases. Victoria Railovna Anashkina, CEO of Amgen in Russia, comments on participation in the Foresight of Health project: "The International Foresight of Health project is a real opportunity to draw attention to innovations in pharmaceuticals, monitor the latest developments and actively implement them in Russia. For Amgen, the world leader in the field of biotechnology, the topic of innovative developments is the highest priority. Today it is no secret to anyone that thanks to biotechnology, drugs for medicine of the 21st century have already been created and will be created. Progress in the field of biotechnology provides new opportunities for the treatment of serious diseases, more effective and safer than existing (traditional) chemical preparations."

The result of the project will be the release of the first atlas "Foresight of Health", which will present in an accessible form all the advanced innovative developments that have become laureates and nominees of the project.

The first edition of the atlas is scheduled for March 2012.

Portal "Eternal youth" http://vechnayamolodost.ru
29.11.2011